Aranesp Awaits Label Transplant As Committee Mulls Alternate Trial Designs
Executive Summary
Amgen avoided an immediate setback when a Cardiovascular and Renal Drugs Advisory Committee meeting on Oct. 18 voted against further restrictions on the use of Aranesp (darbepoetin alfa) in chronic kidney disease (CKD) patients.
You may also be interested in...
Epogen Facing Sales Hit With Reduced Dosing Instructions In ESA Labeling For Renal Disease
Amgen agrees to studies to find what FDA calls "better, safer dose regimen strategies" as ESA labeling revisions create more conservative dosing guidelines for the products.
Chronic Kidney Disease Drug Developers Jockey For Position In Era Of Change
Upheaval in the chronic kidney disease market ranging from FDA’s ongoing re-evaluation of the safety of erythropoietin stimulating agents to impending major changes in Medicare reimbursement for dialysis patients is resulting in a chain reaction of adjustments in drug development strategies.
Chronic Kidney Disease Drug Developers Jockey For Position In Era Of Change
Upheaval in the chronic kidney disease market ranging from FDA’s ongoing re-evaluation of the safety of erythropoietin stimulating agents to impending major changes in Medicare reimbursement for dialysis patients is resulting in a chain reaction of adjustments in drug development strategies.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: